Celecoxib compositions
AssigneePfizer Inc.
InventorsDanchen Gao, Anthony J. Hlinak, Ahmad M. Mazhary, James E. Truelove, Margaret V. Vaughn
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.
Claims25
A pharmaceutical composition comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients, wherein a single dose unit, upon oral administration to a fasting subject, provides a time course of blood serum concentration of celecoxib having at least one of
- (a) a time to reach 100 ng/ml not greater than about 0.5 h after administration;
- (b) a time to reach maximum concentration (Tmax) not greater than about 3 h after administration;
- (c) a duration of time wherein concentration remains above 100 ng/ml not less than about 12 h;
- (d) a terminal half-life (T12) not less than about 10 h;
- and
- (e) a maximum concentration (Cmax) not less than about 200 ng/ml.
Dependencies are inferred from the claim text.